Financial Performance and Strategic Outlook for Evogene Ltd. – Q1 2026

Evogene’s first‑quarter earnings fell short of market expectations, registering a loss of $0.27 per share versus the analyst‑forecasted $0.26. The company’s revenue for the period was $0.4 million, a steep 85.7 % decline from the $2.4 million recorded in Q1 2025. For the full fiscal year, analysts predict a loss of $1.50 per share, compared with $1.08 in the same period last year, and revenue of $1.5 million against $3.9 million previously.

1. Executive Commentary

On May 20, 2026, President & CEO Ofer Haviv addressed the board and investors during a conference call, emphasizing that the 2025 transformation has repositioned Evogene toward execution and scaling of its core technology, ChemPass AI™.“ChemPass AI™ now serves as the single point of innovation for small‑molecule discovery across our pharmaceutical and agricultural pipelines,” Haviv said. “We are accelerating collaborations with technology partners, notably Google Cloud, to embed advanced AI agents that automate dataset generation from complex scientific workflows.”

2. Technological Acceleration

  • ChemPass AI™ – The platform’s generative AI engine can design novel molecules while simultaneously optimizing potency, selectivity, solubility, and other critical parameters at the earliest design stages.
  • Google Cloud Collaboration – In February 2026, Evogene announced a second partnership with Google Cloud to incorporate advanced AI agents into ChemPass AI™, enabling automated generation of unique datasets from complex workflows.
  • Internal Development – Continuous enhancement of the platform through in‑house R&D and partnerships with external technology firms is expected to yield incremental productivity gains.

3. Pipeline Expansion

Pharmaceutical Domain

Evogene expanded its collaboration network in Q1 2026 to four publicly disclosed partnerships:

  1. Systasy Biosciences & LMU University Hospital Munich – Focus on neutrophil‑derived inflammatory diseases.
  2. Queensland University of Technology (QUT) – AI‑driven discovery of therapies for inflammatory diseases and oncology.
  3. Unravel Biosciences – Targeting demyelinating disorders such as multiple sclerosis (MS).
  4. Additional undisclosed collaboration – Details pending release.

These alliances reinforce Evogene’s strategy to secure early‑stage therapeutic candidates, leveraging ChemPass AI™’s multi‑parameter optimization.

Agricultural Domain

Evogene’s AgPlenus subsidiary continues to pursue novel herbicide programs in partnership with Corteva. Simultaneously, an internal fungicide program is advancing through lead optimization, showcasing the efficacy of AI‑driven design coupled with experimental validation. The company’s collaboration with Bayer was terminated following a decision that the target protein did not meet the required production profile, reflecting Evogene’s disciplined exit strategy when a target falls short of commercial viability.

4. Financial Position

  • Market Capitalization – $8.9 million USD (as of 2026‑05‑18).
  • Stock Price – $0.744 USD (closing price on 2026‑05‑18).
  • 52‑Week Range – $2.42 high (2025‑06‑09) to $0.6996 low (2026‑05‑18).
  • Price‑to‑Earnings Ratio – –0.371, indicative of ongoing loss generation.

Despite the earnings miss, the company’s strategic focus on ChemPass AI™ and its expansion into high‑growth therapeutic and agricultural markets position it to recover earnings momentum in the upcoming quarters. Investors should monitor the progression of the newly announced collaborations, the maturation of the internal fungicide program, and the continued integration of AI agents from Google Cloud, as these factors will materially influence Evogene’s profitability trajectory.

Prepared by a senior analyst with deep industry insight.